Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Tackling the future challenges in Systems Biology (FUTURESYSBIO)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Coordination and support actions
Countries involved: Sweden
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-08-01
End date: 2012-01-31
Duration (months): 42.0
Total project cost (EUR): 560748.0
EU funding (EUR): 500000.0
Participants: 2
Project status: CLOSED

The emerging field of Systems Biology is anticipated to have a major impact on the biosciences, moving biology from a phenomenological to a predictive science. Such predictive ability should allow to accurately foresee the outcome of therapeutic interventions with individual patients or to optimise industrial bioprocesses more precisely than has been possible before. Therefore, the results of Systems Biology are expected to have major impact on treatment and diagnosing diseases, health care and the bio-industries. Developing the research field and ensuring exploitation of its results therefore is of major social and economic interest for the European Union. The overall objective of FutureSysBio is to spur and structure the discussion on the development of Systems Biology and thereby provide guidance to stakeholders and scientists. Specifically, the objectives of this project are: (1) To gather and update the research community on latest developments in Systems Biology. (2) To inform and guide funding organisations. (3) To inform and guide pharmaceutical and bio-industries in Europe on developments and opportunities in Systems Biology and thereby enable well-informed corporate decisions. (4) To inform and guide higher education and education funders of challenges and opportunities in interdisciplinary education and training. (5) To inform the media, policy makers and the general public of opportunities, challenges and facts in Systems Biology. To achieve these goals the consortium will organise the following highly visible events: (1) The International Conference on Systems Biology ICSB2008 in Gothenburg. (2) The International Conference on Systems Biology ICSB2010 in Edinburgh or Barcelona. (3) Six high-level expert workshops. (4) Two high-level topical conferences. Different types of dissemination activities tailored for the target audiences will ensure the significant impact that FutureBioSys plans to make on the future development of Systems Biology.

Keywords: systems biology,conferences,workshops,industry,funding organisation,educators,general public
Optimizing suicide prevention programs and their implementation in Europe (OSPI-EUROPE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Germany,Estonia,United Kingdom,Belgium,Netherlands,United Kingdom,Ireland,Hungary,Slovenia,Germany,Portugal,Germany,Austria
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-10-01
End date: 2013-03-31
Duration (months): 54.0
Total project cost (EUR): 3840135.62
EU funding (EUR): 2991727.0
Participants: 15
Project status: CLOSED

Suicide is a serious public health problem in the EU calling for effective interventions. The aim of this project is to provide EU member states with an evidence based prevention concept, concrete materials and instruments for running and evaluating these interventions and recommendations for the proper implementation of the intervention. These aims will be achieved by the following objectives: &gt; Analysis of differences in suicide rates among European countries and harmonisation of procedures for definition, assessment and evaluation of suicidality &gt; Development of a state of the art intervention concept for the prevention of suicidality that considers current evidence-based best practices and international experiences with multilevel interventions, such as that of the European Alliance Against Depression &gt; Implementation of comparable multilevel community based prevention interventions in four European model regions &gt; Evaluation of the interventions in a pre-post, controlled and cross-nationally comparable design concerning effectiveness with respect to both suicides and non-fatal suicidal acts, efficiency (including health economic evaluations), involved processes and finally the interplay between the single intervention measures &gt; Distribution of an optimised suicide preventive intervention concept, corresponding materials and instruments, and recommendations for implementation to policy makers and stakeholders

Keywords: suicide prevention,cross-country comparison,controlled design
Circuit specific approaches to retinal diseases (RETICIRC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,France,Germany,Switzerland
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2011-12-31
Duration (months): 36.0
Total project cost (EUR): 2979560.0
EU funding (EUR): 2250000.0
Participants: 6
Project status: CLOSED

The RETICIR project focuses on neuronal mechanisms of vision from photoreceptor level to visual cortex. Physiological knowledge of the visual system will be used to address pathophysiological neuronal mechanisms of diseases affecting vision. In the project we will identify molecular and cellular disease mechanism of retinitis pigmentosa and glaucoma, and will demonstrate restoration of vision in retinas with degenerated photoreceptors from single neuronal responses in the retina all the way to cortical visual evoked responses and behavioral assays.Blindness in man often results from dysfunction of the retina. For a number of retinal diseases, the retinal circuitry is a major part of the problem. Effective strategies for treatment of those diseases and for all attempts to restore vision, understanding of the retinal circuitries is essential. Our strategy is that understanding the structure and function of specific retinal circuits should be used to find therapies to retinal diseases, like for instance retinitis pigmentosa and glaucoma. Specific circuits can be only studied with cell type specific promoters and therefore the methodology that we will use is the combination of in vivo marked cell types with genetic interference with the function of these cells and state of the art physiological and behavioral approaches.

Keywords: retinal circuitry,retinitis pigmentosa,glaucoma,restoration of vision,channelrhodopsin,neuroprotection,photoreceptor degeneration
Oral Off-patent Oncology Drugs for Kids (03K)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: France,United Kingdom,Italy,United Kingdom,France,France,United Kingdom,France
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-09-01
End date: 2011-08-31
Duration (months): 36.0
Total project cost (EUR): 6836663.0
EU funding (EUR): 5228003.0
Participants: 9
Project status: CLOSED

There is an urgent need for appropriate oral formulations of anticancer drugs for the treatment of paediatric malignancies in children. The goal of the O3K consortium is to develop oral liquid formulations of Cyclophosphamide and Temozolomide, important chemotherapeutics which have been identified in the list of paediatric needs by EMEA (EMEA/197972/2007). Both off-patent drugs are widely used orally for the treatment of childhood cancer. However, the currently available tablets (Cyclophosphamide) and capsules (Temozolomide) are not suitable for use in a paediatric setting, particularly in infants and young children, as it is often impractical for them to be swallowed. This is a major health concern since these children do not readily have direct and safe access to these curative drugs. The NODS® technology represents an innovative oral drug delivery system for drinkable products for children. Drug entrapment in NODS® particles provides gastroprotection, stabilization, chemical protection of labile compounds and taste masking. O3K will conduct the pharmaceutical, clinical and pharmacological studies required for the development of these oral liquid formulations. Upon completion of the project, a dossier containing data required for application for a Paediatric Use Marketing Authorisation (PUMA) will be filed for both products. The EMEA Scientific Advice is already ongoing. O3K will provide access to curative drugs for all children with cancer, improving compliance, ensuring safety for both patient and environment and allowing the development of essential ambulatory treatments. In accordance with ICH guidelines, the development of these agents will lead to improved quality and safety of paediatric drug formulations. The O3K project involves 9 partners (including 5 institutions and 3 SMEs providing expertise in clinical and pharmacological research relating to paediatric oncology along with 1 parents organisation) from three European member states (UK, It and Fr)

Keywords: paediatric malignancies,child-appropriate formulation,puma
Health Equity and Financial Protection in Asia (HEFPA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Netherlands,Belgium,Greece,United Kingdom,China,Cambodia,Indonesia,Philippines,Thailand,Viet Nam
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-06-01
End date: 2013-11-30
Duration (months): 54.0
Total project cost (EUR): 3849138.4
EU funding (EUR): 2885767.0
Participants: 10
Project status: CLOSED

In much of Asia, households are liable for large out-of-pocket payments when they use health services. As a result, many fail to seek care or get inadequate care, while others seek care but end up in financial difficulty. Expanding insurance is one obvious policy solution, but private and community-based insurance schemes have rarely been successful, and social insurance schemes have struggled with the problem of covering the informal sector and the poor; some countries as a result have resorted to a predominantly tax-financed health system. But demand-side factors are only one part of the problem. The cost of health care itself is often unnecessarily high because of weak supply-side incentives. Limited controls on provider prices and type of care delivered can mean that the insured simply end up with higher-priced care. A first strand of the project examines how, in six Asian countries (Cambodia, China, Indonesia, the Philippines, Thailand, and Vietnam), price and other barriers impede use of health care, and result in inequalities in use. It also looks at how households cope with health shocks, and whether they are able to prevent health expenditures and income losses associated with illness from causing sudden and potentially impoverishing drops in consumption. A second strand evaluates the impact of a variety of programs that aim at promoting health care use (especially among the poor), enhance quality and contain costs, and hence help ensure that households are protected from the financial consequences of health shocks. The project builds on successful previous collaborations, but has several innovative features: a focus on the causes of inequity and lack of financial protection, and the impact of programs on both; a mix of cross-country comparative work and in-depth country-specific work; a mix of academic researchers and policy analysts; and an equal emphasis on dissemination to researchers, policymakers and the international development community.

Keywords: health equity - health care access - financial protection - health insurance
Collaborative European effort to Develop Diabetes Diagnostics (CEED3)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,France,United Kingdom,Sweden,Spain,Belgium,Switzerland,Finland,Germany,France,Poland,Spain
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-12-01
End date: 2012-11-30
Duration (months): 48.0
Total project cost (EUR): 3830004.0
EU funding (EUR): 3000000.0
Participants: 12
Project status: CLOSED

CEED3 (Collaborative European Effort to Develop Diabetes Diagnostics) has as its central objective, the development of diagnostic tools to differentiate specific subgroups of diabetic patients to allow individualisation of patient care. CEED3 will achieve this by integrating basic science findings from animal models, cell studies, and large scale genetic studies with clinical observations and testing of patients’ phenotype. The development of diabetes diagnostic tools will involve a clearly defined process of discovery of potential novel genetic and non-genetic biomarkers, validation within test and population based data samples, development of a clinical application and then dissemination of this application. The areas of focus for the diabetes diagnostics will be three areas where there is potential for considerable improvement in care and reduction in the burden of diabetes: the identification of patients with specific subgroups of monogenic diabetes, the identification of non diabetic and diabetic subjects with initial pancreatic beta-cell dysfunction at high risk of rapidly deteriorating glycaemia and the detection of diabetic patients at increased risk of vascular complications. For each of these patient groups the identification of the subgroups will result in improved clinical care by allowing treatment to be tailored for the individual patient. Therefore, the goal of this proposal is to make a rapid translation from scientific discoveries to improved care for diabetic patients. CEED3 has assembled the best researchers, clinical samples and technical expertise in Europe to realise this goal.

Keywords: diabetes diagnostics
Cultivated Adult Stem Cells as Alternative for Damaged tissue (CASCADE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: France,Germany,Italy,France,Romania,United Kingdom,United Kingdom,Germany,Germany,Germany,Italy
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2011-12-31
Duration (months): 36.0
Total project cost (EUR): 5130179.0
EU funding (EUR): 2979667.0
Participants: 16
Project status: CLOSED

Rapid progress in stem cell research pave the way for the development and use of new cell therapy products in regenerative medicine. The objective of CASCADE is to provide the European Community with unique expertise which focuses on the GMP production of mesenchymal stem cells (MSC) and their use in treating skin and corneal wounds, so that quality and safety criteria are paramount and match therapeutic expectations. Commencing with known procedures, CASCADE will develop innovative technologies based on the expertise of its partners. Among our research themes, the specific issue of multiple recipients and universal donors will be investigated. To this end, human MSC will be derived from 4 tissues, bone marrow, fat tissue, cord blood and amniotic membrane, according to good manufacturing practice (GMP). Phenotypic identity of GMP produced MSC, their genetic status and their potential for transformation will constitute the basis for establishing standards for controlling cell production. The efficacy of GMP produced MSC will be tested in in vitro and in vivo models, and the immunological consequences of their use will be studied. Moreover, during the whole CASCADE initiative, ethical and legal issues raised as a result of MSC therapies will be considered. Direct collaboration with two clinical networks will allow CASCADE to finely tune production specifications, and define optimal clinical protocols for these MSC-based cellular therapies. CASCADE will therefore gather together leading European cell therapy laboratories with unrivalled expertise in the production of therapeutic cells and in MSC biology, four SMEs with specific know-how in GMP production of cells and two clinical networks in dermatology and ophthalmology. The outcome will be a consortium that encompasses all the technologies and skills required to efficiently develop innovative technologies for the production of clinical grade MSC and to translate this production into a cell drug to repair wounds.

Keywords: mesenchymal stem cells,stem cells,gmp production,cell therapy,tissue therapy
Combinatorial synthesis of peptide arrays with a laser printer (PEPLASER)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Germany,Germany,Bulgaria,Germany,Austria,Poland,Germany,Germany,Germany,Austria,Poland
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2011-12-31
Duration (months): 36.0
Total project cost (EUR): 4028614.76
EU funding (EUR): 2988450.0
Participants: 12
Project status: CLOSED

Our particle-based method allows us to synthesise high complexity peptide arrays by combinatorial synthesis and for an unrivalled prize. We plan to further develop this new technology up to the level of robust prototype machines, and mate it to bioinformatics and readout tools. Together, our procedure(s) should boost the field of proteomics in a similar way as the lithographic technologies did with the field of genomics. Central to our novel method are the activated chemical building blocks that are “frozen” within solid amino acid particles. Thereby, we can use a colour laser printer to send them to defined addresses on a 2D support, where the particles are simply melted to induce a spatially defined coupling reaction of now freed amino acid derivatives. By repeated printing and melting cycles this simple trick yields high complexity peptide arrays. Based on existing pre-prototypes, we will develop a user-friendly peptide laser printer that spatially defined addresses our 20 different amino acid toners in high resolution to a support (WP1), and a scanner that especially fast and sensitive reads out the large formats delivered by the peptide laser printer (WP2). The increased production of amino acid toners and array supports are other bottlenecks in the output of peptide arrays that are tackled in WP3. This should allow us to increase the output of individual peptide spots from currently 0,5 Million to &gt;10 Million peptides per month. Finally, to foster a market for high complexity peptide arrays, we will work out paradigmatic application examples in WP4. These aim to directly screen for antibiotic or apoptosis inducing D-peptides, and for the comprehensive readout of the different antibodies that patrol the serum of autoimmune patients. Based on user-friendly prototype machines, on first paradigmatic application examples for high complexity peptide arrays, and shielded by a strong patent, the participating SMEs will commercialise this new technology.

Keywords: peptide arrays,scanner,laser printer,combinatorial peptide synthesis
Health Services Research into European Policy and Practice: preparation and organisation of a European Health Services Research Conference (HSREPP)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Coordination and support actions
Countries involved: Netherlands,Germany,Denmark,Netherlands,United Kingdom
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-03-01
End date: 2011-02-28
Duration (months): 24.0
Total project cost (EUR): 755696.0
EU funding (EUR): 699961.41
Participants: 5
Project status: CLOSED

This proposal addresses the objectives of the call for a Health Services Research Conference. Our aim is to identify, evaluate and improve the contribution of HSR to the health policy process at the level of Member States and the EU. For this purpose we will organise a working conference aimed at active involvement of researchers (both established as well as upcoming experts), together with policy makers in the European Union and its Member States. As leading authorities for HSR and policy, they both constitute main target groups but are also crucial sources of information. To prepare the conference we will therefore organise a pre-conference consultation to clarify their needs for HSR inputs. In addition, we will map the main issues in the field of HSR and organise an open call to provide an overview of scientific insights into the topic. Given the broad nature of HSR the field is divided into five main areas, around which the conference will be centred: - Health (care delivery) systems; - Health care organisations and professional practices; - Health Technology Assessment; - Benchmarking & performance indicators (crosscutting all areas); - Relationships between research & policy (crosscutting all areas). Relating the needs from the users of HSR knowledge to the state-of-the-art and research presentations during the conference results in tailored research questions for a policy supportive HSR agenda. The conference will be held in April 2010 and will include invited groups to achieve equal representation of expertise throughout the EU, as well as an open call to interested parties. Its follow-up will consist of the production of a final synthesis report and Policy briefs. These will include a research agenda for the EC and other stakeholders with special attention to the geographical coverage of HSR in Europe. Scientific articles for the research community include a special issue of the Journal of Health Services Research & Policy.

Keywords: hsr conference,state-of-the-art,stakeholder consultation,research agenda priority setting